Ticker
$ABBV
1 catalyst touching ABBV in the last 60 days, newest first, each with the price move that followed.
- 52
ABBV Q3 2026 guidance cut by $0.11 per share on IPR&D milestones
AbbVie incurred $216 million in acquired IPR&D and milestone expenses in Q3 2026, reducing both GAAP and adjusted EPS by $0.11 per share. The company lowered full-year adjusted EPS guidance to $13.76–$13.96 from the prior range that excluded post-Q2 IPR&D charges, representing a material but previously disclosed category of uncertain costs.
ABBV ▼SEC 8-K · 5 Oct 2026, 20:07 UTC
Information only. AURA does not give buy or sell recommendations.